Nurix Therapeutics (NRIX) Invested Capital: 2019-2025
Historic Invested Capital for Nurix Therapeutics (NRIX) over the last 5 years, with Aug 2025 value amounting to $372.3 million.
- Nurix Therapeutics' Invested Capital fell 1.22% to $372.3 million in Q3 2025 from the same period last year, while for Aug 2025 it was $372.3 million, marking a year-over-year decrease of 1.22%. This contributed to the annual value of $527.0 million for FY2024, which is 162.85% up from last year.
- Nurix Therapeutics' Invested Capital amounted to $372.3 million in Q3 2025, which was down 16.83% from $447.6 million recorded in Q2 2025.
- Nurix Therapeutics' Invested Capital's 5-year high stood at $527.0 million during Q4 2024, with a 5-year trough of $168.7 million in Q1 2024.
- In the last 3 years, Nurix Therapeutics' Invested Capital had a median value of $370.7 million in 2024 and averaged $337.5 million.
- As far as peak fluctuations go, Nurix Therapeutics' Invested Capital plummeted by 38.42% in 2024, and later soared by 184.99% in 2025.
- Quarterly analysis of 5 years shows Nurix Therapeutics' Invested Capital stood at $342.3 million in 2021, then fell by 11.28% to $303.7 million in 2022, then slumped by 33.98% to $200.5 million in 2023, then surged by 162.85% to $527.0 million in 2024, then dropped by 1.22% to $372.3 million in 2025.
- Its last three reported values are $372.3 million in Q3 2025, $447.6 million for Q2 2025, and $480.9 million during Q1 2025.